Below is a table with a list of the market segments demonstrating greater than 10% compound annual growth rate for the associated region through 2022, drawn from our reports on tissue engineering & cell therapy, wound management, ablation technologies, stroke, peripheral stents, and sealants/glues/hemostats. Products with over 10% CAGR in sales are shown in descending order of CAGR.
The market for stents used in peripheral vascular indications — inclusive of stent grafts, and arterial and venous stents — is growing at an aggregate 6.2% CAGR from 2016 to 2020, which belies much stronger growth in specific subsets, especially in emerging markets like Asia/Pacific.
The aggregate compound growth rates for peripheral stent markets in each global region is shown below, with growth rates weighted by individual segment sales:
U.S.: 9.5% Western Europe: 5% Asia/Pacific: 21.3% Rest of World: 13.9%
Peripheral stent products include the following, each of which is growing in sales at varying rates above and below the aggregregate regional sales growth:
Peripheral Arterial Stenting
– Bare Metal Stent Devices
– Drug Eluting Stent Devices
Aortic Aneurysm Repair
– Abdominal AA Stent-Grafts
– Thoracic AA Stent-Grafts
Peripheral Venous Stents
Worldwide Peripheral Stent Market by Product Category, 2015 and 2020
Interventional devices, offering MIS advantages, have preempted surgical caseload, and have expanded the treatable patient population. Multiple competitive alternatives are effective for high volume procedures for treatment of coronary artery, peripheral artery and other cardiovascular pathologies.
Clinicians have changing demands, sometimes very much in alignment with what manufacturers see as needs (it is good to point out their need before they see it).
Older populations are good for medtech — let’s be honest. (Yes, the “aging demographic” argument has been made again, but it is particularly true for interventional procedures, which are used disproportionately in older populations in accordance with age-based incidence rates in cardiovascular disorders.)
Cardio device manufacturers both lead and follow the market. Technologies that lower invasiveness, reduce complications, reduce repeats, increase outcomes, lower costs, and provide other benefits drive new procedure volume. When new technologies are progressively introduced, they have variable impacts on procedure volume, either displacing caseload or tapping new. The timing and relative impact of new technology emerging can cause abrupt shifts in caseload, procedures — and revenue.
Here are the top procedures for surgical and interventional cardiology:
Coronary artery bypass grafting
Coronary angioplasty and stenting coronary/mechanical and laser atherectomy
Ventricular assist device placement
Total artificial heart implantation
Donor heart transplantation
Lower extremity arterial bypass surgery
Percutaneous transluminal angioplasty (PTA) and bare metal stenting
PTA and drug-eluting stenting
PTA with coated balloons
Mechanical and laser atherectomy
Catheter-directed thrombolysis and thrombectomy
Aortic aneurysm repair
Vena cava filter placement
Mechanical venous thrombectomy
Venous angioplasty and stenting
Carotid artery stenting
Cerebral aneurysm and AVM surgical clipping
Cerebral aneurysm and AVM coiling & flow diversion